Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor|
|Abstract:||In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.|
|Inventor(s):||Evans; Ronald M. (La Jolla, CA), Mangelsdorf; David J. (Duncanville, TX), Heyman; Richard A. (Encinitas, CA), Boehm; Marcus F. (San Diego, CA), Eichele; Gregor (Houston, TX), Thaller; Christina (Houston, TX)|
|Assignee:||The Salk Institute for Biological Studies (La Jolla, CA) Baylor College of Medicine (Waco, TX) Ligand Pharmaceuticals, Inc. (San Diego, CA)|
1. A composition in unit dosage form for oral administration, said composition consisting essentially of: as an active ingredient, a compound selected from the group
consisting of 9-cis retinoic acid, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable hydrolysable esters thereof, and a pharmaceutically acceptable carrier suitable for oral administration.
2. A composition in unit dosage form for oral administration, said composition consisting of: as an active ingredient, a compound selected from the group consisting of 9-cis retinoic acid, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable hydrolysable esters thereof, and a pharmaceutically acceptable carrier suitable for oral administration.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.